Company profile
BioCardia, Inc.
NASDAQ: BCDA · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
29DFH 18DQ 51GM 6SS 58
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$8.2M
Employees
17
as of 2026-08-23
Market cap
$15.0M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$8.2M-$8.2M2025
Operating income-$8.3M-$8.3M2025
Total assets$3.4M$3.4M2025
Liabilities$2.5M$2.5M2025
Equity$895.0k$895.0k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
Collaboration Agreement100%
By geography
Not disclosed.
The read
What is BioCardia, Inc.’s revenue?
BioCardia, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Palatin Technologies, Inc.40DInhibitor Therapeutics, Inc.29DBiomind Labs Inc.——Adagio Medical Holdings, Inc.24DSynlogic, Inc.45DPhio Pharmaceuticals Corp.41DNeighbors
Santa Clara →Key facts
CEOPeter A. Altman
SectorHealthcare
IndustryBiotechnology
HeadquartersSunnyvale, CA
ExchangeNASDAQ: BCDA
Employees17
IPO date1996-11-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.